Valeo Health, a leading innovator in AI-driven at-home healthcare, has successfully closed a $12 million Series B funding round, bringing its total capital raised to $20 million. This investment will fuel the company’s mission to expand its personalized, science-backed healthcare solutions across the KSA, UAE, and the wider GCC region.
Co-founded by Sundeep Sahni, Nadine Karadag, and Ankur Majumder, Valeo Health utilizes its proprietary Longevity technology to deliver tailored treatment plans, addressing individual health needs. The funding round, led by Flintera, saw participation from existing investors like Nuwa Capital and FJ Labs, alongside new investors Oraseya and Eirad.
“This funding enables us to scale our AI technology, enhance our product offerings, and expand our reach,” said CEO Sundeep Sahni, emphasizing the company’s commitment to proactive healthcare. Nadine Karadag highlighted the investment’s validation of the team’s efforts and its role in scaling personalized healthcare.
Investors expressed strong confidence in Valeo’s vision and execution. Flintera recognized Valeo’s potential to shape the future of preventive care, while Nuwa Capital praised the company’s “strong cross-border potential and impressive year-over-year growth.”
Valeo Health’s success in delivering real-time insights and tailored wellness solutions has solidified its position as a trusted name in the region’s health-tech sector. This new funding will enable the company to further revolutionize personalized healthcare, making it more accessible to individuals across the GCC.
